CA2390646A1 - Compositions et methodes pour reguler l'inhibiteur endogene de l'atp-synthase, et pour le traitement du diabete - Google Patents

Compositions et methodes pour reguler l'inhibiteur endogene de l'atp-synthase, et pour le traitement du diabete Download PDF

Info

Publication number
CA2390646A1
CA2390646A1 CA002390646A CA2390646A CA2390646A1 CA 2390646 A1 CA2390646 A1 CA 2390646A1 CA 002390646 A CA002390646 A CA 002390646A CA 2390646 A CA2390646 A CA 2390646A CA 2390646 A1 CA2390646 A1 CA 2390646A1
Authority
CA
Canada
Prior art keywords
organelle
atp
cells
sequence
mitochondria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390646A
Other languages
English (en)
Inventor
Christen M. Anderson
William Clevenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2390646A1 publication Critical patent/CA2390646A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)

Abstract

La présente invention concerne des compositions et des méthodes pouvant modifier la production d'ATP mitochondrial, y compris des immunodétections et des dosages fonctionnels exploitant les interactions d'IF1 avec l'ATP-synthase. L'invention concerne aussi des méthodes utilisées dans des dosages de criblage pour un composé pouvant réduire l'hydrolyse de l'ATP mitochondrial et/ou augmenter la synthèse de l'ATP mitochondrial, ainsi que des une compositions pharmaceutiques identifiées par ces méthodes. L'invention concerne en outre des méthodes de traitement du diabète, notamment le diabète non insulino-dépendant, au moyen d'un agent identifié selon les méthodes de l'invention.
CA002390646A 1999-11-10 2000-11-10 Compositions et methodes pour reguler l'inhibiteur endogene de l'atp-synthase, et pour le traitement du diabete Abandoned CA2390646A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16462299P 1999-11-10 1999-11-10
US60/164,622 1999-11-10
PCT/US2000/030862 WO2001034833A2 (fr) 1999-11-10 2000-11-10 Compositions et methodes pour reguler l'inhibiteur endogene de l'atp-synthase, et pour le traitement du diabete

Publications (1)

Publication Number Publication Date
CA2390646A1 true CA2390646A1 (fr) 2001-05-17

Family

ID=22595338

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390646A Abandoned CA2390646A1 (fr) 1999-11-10 2000-11-10 Compositions et methodes pour reguler l'inhibiteur endogene de l'atp-synthase, et pour le traitement du diabete

Country Status (5)

Country Link
EP (1) EP1230379A2 (fr)
JP (1) JP2003527835A (fr)
AU (1) AU1759901A (fr)
CA (1) CA2390646A1 (fr)
WO (1) WO2001034833A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072739A1 (en) * 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
WO2002024204A2 (fr) * 2000-09-20 2002-03-28 Mitokor Inhibition de l'antiport calcium/sodium mitochondrial
EP1430155A2 (fr) * 2001-09-05 2004-06-23 Pride Proteomics A/S Proteines impliquees dans le diabete de type 2
KR102239074B1 (ko) * 2018-09-14 2021-04-14 고려대학교 산학협력단 IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물
KR102248110B1 (ko) * 2018-10-02 2021-05-06 고려대학교 산학협력단 IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 항암용 약학 조성물
KR102239075B1 (ko) * 2018-10-02 2021-04-14 고려대학교 산학협력단 IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물
KR102276379B1 (ko) * 2018-10-02 2021-07-14 고려대학교 산학협력단 IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물
KR20230135586A (ko) * 2021-01-24 2023-09-25 마이클 데이비드 포레스트 Atp 합성효소 억제제 - 미용 및 치료 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1998033909A1 (fr) * 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Nouvelle proteine humaine inhibitrice de l'atpase
GB9824282D0 (en) * 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus

Also Published As

Publication number Publication date
WO2001034833A2 (fr) 2001-05-17
JP2003527835A (ja) 2003-09-24
AU1759901A (en) 2001-06-06
WO2001034833A3 (fr) 2002-01-17
EP1230379A2 (fr) 2002-08-14

Similar Documents

Publication Publication Date Title
US20040072739A1 (en) Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US20020049176A1 (en) Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
Seibel et al. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases
JP2021534798A (ja) ゲノムを調節するための方法及び組成物
BR112020005323A2 (pt) polinucleotídeos, composições e métodos para edição de genoma
KR102544051B1 (ko) 인간화된 ttr 유전자좌를 포함하는 비인간 동물 및 사용 방법
US7223556B1 (en) Targeted proteolysis by recruitment to ubiquitin protein ligases
EP2501414B1 (fr) Dégron smndelta7 : nouvelles compositions et procédés d'utilisation
Longman et al. Multiple interactions between SRm160 and SR family proteins in enhancer-dependent splicing and development of C. elegans
US20200362008A1 (en) Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
US20230151342A1 (en) Zinc finger degradation domains
CA2390646A1 (fr) Compositions et methodes pour reguler l'inhibiteur endogene de l'atp-synthase, et pour le traitement du diabete
WO2001035096A2 (fr) Modulation de la masse et de la fonction mitochondriales permettant de traiter des maladies, et de cibler et de decouvrir des medicaments
US20030026781A1 (en) Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US20100310532A1 (en) Gene targets in anti-aging therapy and tissue repair
Boustead et al. Identification and characterization of a cDNA and the gene encoding the mouse ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein
SE523043C2 (sv) Humant intestinalt Npt2B
US6084063A (en) Signal transduction inhibitors of allergic reactions
EP0984987A2 (fr) COMPOSITIONS PHARMACEUTIQUES COMPRENANT UN PRECURSEUR DE RECEPTEUR DE LAMININE SOLUBLE OU UN COMPOSE BLOQUANT L'INTERACTION DU PRECURSEUR DE RECEPTEUR AVEC PrPS?c OU PrP?c
EP1582586A1 (fr) Proteine associee a l'apoptose et son utilisation
JP2020529836A (ja) ミオパチーの処置における使用のためのｍｔｍｒ２−ｓポリペプチド
EP1161442A2 (fr) Proteine de voies d'exocytose et leurs procedes d'utilisation
US9243234B2 (en) Sequence-specific MRNA interferase and uses thereof
Pinello et al. Novel requirements for HAP2/GCS1-mediated gamete fusion in Tetrahymena.
RU2784927C1 (ru) Отличные от человека животные, включающие в себя гуманизированный ttr локус, и способы применения

Legal Events

Date Code Title Description
FZDE Dead